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and EF-CCRT (42 patients) followed by high dose rate brachytherapy. 
Data regarding the safety profile, response rates and occurrence of 
local, para-aortic or distant failure were recorded. 
Results: Witha median follow-up time of 5 years (range, 4-5.5), EF-
CCRT ( 38 patients) was associated with better 5-year disease-free 
survival of 80.3% compared with 69.1% in 36 patients treated with WP-
CCRT (p = 0.04). The PALN control rates were 97.1% and 82.1% in EF-
CCRT and WP-CCRT respectively (p = 0.03) and distant control rates 
were 94.7% in EF-CCRT and 80.6% in WP-CCRT (p = 0.02). The 5-year 
overall survival rates were 72.4% for EF-CCRT and 60.4% for WP-CCRT 
(p = 0.04). No difference in acute toxicity profile was seen in both 
groups and during a median follow up of 60 months, one patient 
(2.6%) in EF-CCRT group experienced intestinal obstruction.  
Conclusions: Prophylactic EF-CCRT showed better para-aortic nodal, 
distant control, disease-free survival, and overall survival rates as 
those of WP-CCRT with acceptable toxicity in patients with radiologic 
negative PALN locally advanced cervical cancer. 
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Purpose/Objective: Diffusion Weighted MRI (DW-MRI) is used for 
diagnostic cancer imaging and may have value for monitoring of tumor 
response to radiotherapy (RT). In this study, DW-MRI was evaluated as 
a non-invasive biomarker for prediction of local failure in RT of locally 
advanced cervical cancer. 
Materials and Methods: 52 patients were treated with 45-50Gy whole 
pelvis external beam RT (EBRT) and 2 fractions of brachytherapy (BT). 
Patients underwent MRI examination 3 times during treatment with 
the BT applicator in situ: 1) a preplanning MRI (BT0) one week prior to 
first BT, 2) at time of first BT and 3) at time of second BT (BT2) one 
week after first BT. Dose-planning for BT was based on T2-weighted 
MRI following the GEC-ESTRO guidelines. DW-MRI (b=0, 600, 1.000 
s/mm2) was included in all three MRIs using a 1.5T MRI. Median 
follow-up time from start of treatment was 24 month (min/max: 6/46 
month). Blinded visual assessment of signal intensities on DW-MRI, 
b=1.000 s/mm2 at time of BT0 was evaluated for hyper-intensity at 
tumor site and was found in 22/52 patients (table 1).Images of 
Apparent Diffusion Coefficients (ADC) were calculated for the 
22patients. The relationship between local failure and ADC, change in 
ADC and volumes was investigated. 
Results: There was asignificant correlation between local failure 
(Fischer’s exact test p=0.021) and presence of hyper-intense signal on 
DW-MR images at b=1.000 s/mm2 at time of BT0 (Table 1). The ADC 
for DWI ROI at BT0 in patients with local control (1.21±0.19 x10-3 
mm2/s) compared to failures (1.31±0.24 x10-3 mm2/s) was not 
significant(p=0.21). There was no significant change in ADC from BT0 
to BT2 (p = 0.44).There was a significant decrease in the volume of 
the DWI ROI for both patients with local control (VBT0 = 5.06±4.72 
cm3 to VBT2= 1.51±1.36 cm3) (p = 0.016) and failures (VBT0= 
7.54±5.02 cm3 to VBT2 = 4.12±3.12 cm3) (p =0.003). The mean DWI 
ROI volume at time of BT2 was significantly larger (p=0.006)in patients 
with failures as compared to those with local control.  
 
  
Conclusions: The presence of hyper-intense tumor signal at highly 
diffusion sensitive images (b = 1.000s/mm2) at time of BT seems to be 
a strong indicator for increased risk of persistent local disease or local 
recurrence. However, the qualitative and subjective nature of the 
visual evaluation of hyper-intense signal at DW-MR images is an issue 
that should be addressed in future work. At this time of treatment the 
ADC appears stable before and after the BT fraction and it was not 
possible to use the ADC to differentiate between responders and non-
responders. The study shows that the tumor delineated by the DWI 
ROI decreases during treatment although the ADC value did not 
change. This study indicates that DW-MRI may be of value for 
monitoring RT-treatment and predicting local failure already during 
treatment.  
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Purpose/Objective: This study aims to determine candidate genes 
and chromosomal imbalances capable of predicting metastasis 
occurrence in a homogenous population of patients with rectal 
cancer. 
Materials and Methods: Fresh frozen tumor tissues from 80 patients 
with rectal cancer were analyzed using Affymetrix HG-U133 Plus 2.0 
gene expression arrays and high-resolution Illumina single nucleotide 
polymorphism (SNP) arrays. Median follow-up was 102 (1-146) months. 
Endpoints of the study were metastasis-free survival (MFS) and 
cancer-specific survival (CSS). The prognostic value of two validated 
colon gene expression signatures was also tested in this cohort. 
Results: We were unable to derive a significant predictor of prognosis 
based on gene expression, since only a few genes were significantly 
associated with MFS or CSS after multiple testing corrections. In 
contrast, deletions of 8p and 1p36-35 correlated with worse MFS (P = 
0.005 and P = 0.01, respectively) and CSS (P = 0.001 and P = 0.01, 
respectively). Multivariate analysis identified -8p as an independent 
prognostic factor for MFS (P = 0.04) and CSS (P = 0.003). A genomic 
signature of colon cancer was not significantly associated with 
prognosis, whereas another one significantly predicted MFS in T3 
tumors (P = 0.04). 
Conclusions: This study shows for the first time in rectal cancer an 
independent correlation of -8p with MFS and CSS. Specific prognostic 
factors may apply to rectal cancer, justifying the need for 
homogeneous rectal cancer samples in prognostic studies.  
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Purpose/Objective: Target volume definitions for radiotherapy in 
pancreatic ductal adenocarcinoma (PDAC) vary substantially. Some 
groups aim to treat only the primary tumour whereas others include 
elective lymph nodes (eLN’s). ELN’s close to the primary tumour are 
often included unintentionally within the treatment volume, 
depending on the respective philosophies. We aimed to measure the 
percentages of anatomical coverage of the eLN’s comparing four 
different guidelines. 
Materials and Methods: PTVs were contoured using planning-CT’s of 
eleven patients with PDAC based on the Oxford, RTOG, Michigan and 
SCALOP guidelines. CTVs included the peripancreatic, paraaortic, 
paracaval, celiac trunk, superior mesenteric and portal vein lymph 
node areas. Volumetric comparisons of coverage of all eLN regions 
were conducted to illustrate the differences between the 4 contouring 
strategies. 
Results: Significant differences in PTV sizes were observed in the 
following order: RTOG > Oxford > SCALOP > Michigan (620, 450, 230, 
160 ccm, respectively). A large variation of eLN coverage was found 
for the respective subregions according to the respective guidelines. 
The eLN areas of highest risk, i.e. posterior peripancreatic nodes were 
covered best in Oxford and RTOG definitions. Much of the additional 
volume of the latter two compared to Michigan and SCALOP was 
related to paraaortic and portal venous eLNs. 
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Conclusions: To our knowledge, this is the first study to directly 
compare the percentage of anatomical coverage of eLN’s by four PTVs 
in the same patient cohort. Potential practical consequences are 
discussed in detail. Knowing the specific risk of each eLN region allows 
to derive a moderate expansion of the primary tumour volume to 
include eLN regions at highest risk without significant normal tissue 
dose increase.  
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Purpose/Objective: Preoperative chemoradiotherapy (CRT) has been 
established as the standard of care for patients with cT3-4 rectal 
cancer. However, a benefit on overall survival (OS) could not be 
demonstrated with the addition of concomitant chemotherapy. We 
explored prospectively preoperative intensity-modulated and image-
guided radiotherapy (IMRT-IGRT) with a simultaneous integrated boost 
(SIB) as an alternative strategy, of which first results showed a limited 
acute toxicity profile and promising 2-year local control (LC). Here, 
we report clinical outcome and late toxicity after a median follow-up 
of 54 months. 
Materials and Methods: A total of 108 patients were treated 
preoperatively with IMRT-IGRT using the Tomotherapy Hi-Art II 
system, delivering a dose of 46 Gy in daily fractions of 2 Gy to the 
mesorectum and draining lymph nodes, without concomitant 
chemotherapy. Fifty-seven patients (53%) displayed an anticipated 
circumferential resection margin (CRM) of less than 2 mm based on 
magnetic resonance imaging and received a SIB to the tumor up to a 
total dose of 55.2 Gy (boost group). Late side effects were scored 
using the National Cancer Institute Common Terminology Criteria for 
Adverse Events version 3.0. 
Results: Grade ≥ 2 late diarrhea was recorded in 11% of the patients. 
The absolute incidence of grade ≥ 3 late gastrointestinal and urinary 
toxicity was 9% and 4%, respectively, with a 13% rate of any grade ≥ 3 
late toxicity. The actuarial 5-year LC, progression-free survival (PFS) 
and OS were 97%, 68%, and 68%. On multivariate analysis, R1 resection 
(CRM ≤ 1 mm) (p=0.03) and pN2 disease (p=0.04) were associated with 
significantly impaired PFS and OS. Dworak grade 3-4 regression 
showed improved PFS on univariate analysis (p=0.03).  
Conclusions: The use of preoperative IMRT-IGRT with a SIB resulted in 
an acceptable late toxicity profile in T3-4 rectal cancer patients. The 
implementation of a SIB in a patient population at risk for local 
recurrence yielded a high 5-year LC rate, comparable to the rates 
observed after preoperative CRT.  
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Purpose/Objective: As neoadjuvant treatment and total mesorectal 
excision (TME) has dramatically improved local control during the last 
two decades, distant recurrences now primarily determine outcome in 
patients with rectal cancer. The introduction of preoperative 
chemoradiotherapy (CRT), however, has also changed the importance 
of histopathological parameters. The objective of this study is to 
evaluate which factors determine outcome, focusing on the 
contribution of clinical factors and histopathological response after 
CRT, in the development of distant recurrences in particular. 
Materials and Methods: Between 2004 and 2008, all consecutive 
patients with MRI-defined locally advanced rectal cancer (LARC), 
without synchronous metastases, treated with CRT (25x2Gy during 
weekdays with capecitabine 825 mg/m2 days 1-33) followed by TME 
after 6-8 weeks, were included. Adjuvant chemotherapy was not 
standard. Central revision of histopathology followed using TNM, 5th 
edition. Histological tumour regression grade (TRG) was scored with a 
4-tier system (complete response, near complete response, response, 
poor response). Univariate and logrank analysis were performed to 
identify predictors and prognosticators. 
Results: For this 107 patients with a median follow-up of 44 months, 
the distal recurrence free interval (DRFI), DFS and OS 3-year rates 
were 82%, 73% and 87%, respectively. Of the 23 patients developing 
distant recurrences, 11 occurred within a year after surgery (Fig 1). 
Slides of the resection specimens were analysed and revealed 18% 
pCR, 13% near pCR, 55% response, and 14% poor response. A positive 
CRM, ypT3-4 and presence of poor prognostic features (lymphangio 
invasion or perineural growth) were associated with a poor response. 
Four of the 19 patients with a pCR still harboured nodal metastases. 
Six of 14 patients with a near pCR still had ypT3 disease and 8/14 
were still node positive. In addition, near pCR was associated with a 
relatively poor outcome: 5 out of 14 patients developed distant 
metastases. TRG was a powerful discriminator of DRFI, DFS and OS. In 
addition ypT, ypN, presence of tumour deposits (TD) and the presence 
of acellular mucin lakes, were associated with a decreased DRFI, and 
remained significant after adjusting for TRG. Whereas ypN, TD, 
mucinous histology and acellular mucin lakes were associated with 
distant recurrence within a year. 
 
 Conclusions: In this well-defined and uniformly treated cohort of 
LARC patients, a ypCR predicts excellent outcome, while patients with 
a near pCR still have a high risk of developing distant recurrences 
(36%). The high number of near pCR patients with ypT3 or ypN1/2 
disease demonstrates that wait and see policies in locally advanced 
rectal cancer patients should be applied with extreme caution and 
care. 
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Purpose/Objective: In rectal cancer, histopathologic complete 
response to neoadjuvant radiation/chemoradiation therapy (RT/CRT) 
commonly translates into long-term survival benefits, and some 
investigators are currently advocating a non-surgical 'wait-and-see' 
approach in patients achieving complete clinical response. Using 
organ-infiltrating rectal cancer as model, we aimed at identifying the 
actual ('true') frequency of tumor down-staging following neoadjuvant 
RT/CRT, by means of determining the false-negative rate of 
conventional histopathologic tumor response evaluation. In doing so, 
we developed the diagnostic procedure of magnetic resonance- (MR) 
guided histopathology. 
Materials and Methods: Ninety-two patients that had received 
neoadjuvant treatment and proceeded to extended total mesorectal 
excision were identified from the institutional database. For each 
patient, the study radiologist and pathologist separately interpreted 
preoperative MR images and histologic preparations from the surgical 
specimen, to determine whether tumor down-staging had resulted. In 
cases of discrepancy after the separate yT staging (52 patients), 
histologic sections were jointly reassessed for residual tumor in areas 
